ESR1 and breast carcinoma: In agreement with the report by Lai et al that SELENBP1 expression was largely decreased in the more malignant cell line MB231 but not in the less aggressive MCF7 [37], and ER+ and luminal breast cancer usually has a better prognosis than the ER– and basal subtype breast cancer, we found that most ER+ and luminal breast cancer cells expressed high level of SELENBP1 but not ER– and basal ones.